Effectiveness, tolerability and practical application of the newer generation anti-obesity medications

Drugs in Context

Volumn 5, Issue , 2016, Pages

  MacDaniels, Jeffrey S ^a   Schwartz, Thomas L ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Anti obesity; Bupropion; Liraglutide; Lorcaserin; Naltrexone; Number Needed to Harm (NNH); Number Needed to Treat (NNT); Orlistat; Phentermine; Topiramate; Weight loss

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; LIRAGLUTIDE; LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TETRAHYDROLIPSTATIN;

ACUTE PANCREATITIS; BODY MASS; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; NAUSEA; NUMBER NEEDED TO HARM; NUMBER NEEDED TO TREAT; OBESITY; PARESTHESIA; PRESCRIPTION; REVIEW; SEIZURE; STATISTICAL ANALYSIS; STEATORRHEA; SYSTEMATIC REVIEW; VOMITING; WEIGHT REDUCTION;

EID: 84975865212     PISSN: 17451981     EISSN: 17404398     Source Type: Journal    
DOI: 10.7573/dic.212291     Document Type: Review

References (14)

1. Yang L, Colditz GA. Prevalence of overweight and obesity in the United States, 2007-2012. JAMA Intern Med. 2015 Aug;175(8):1412-3. http://dx.doi.org/10.1001/jamainternmed.2015.2405
2. Centre for Evidence-Based Medicine. Number needed to treat [Internet]. Oxford: Nuffield Department of Primary Care Health Sciences; 2014 [cited 2015 Jul 7]. Available from: http://www.cebm.net/number-needed-to-treat-nnt/
3. Andrade C. The numbers needed to treat and harm (NNT, NNH) statistics - what they tell us and what they do not. J Clin Psychiatry. 2015;76(3):e330-e33. http://dx.doi.org/10.4088/JCP.15f09870
4. Contrave NDA. [cited 2015 July 4]. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm235671.pdf.
5. Apovian CM, Aronne L, Rubino L, Still C, Wyatt H, Burns C, Kim D, Dunayevich E. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21:935-43. http://dx.doi.org/10.1002/oby.20309
6. Food and Drug Administration. FDA briefing document NDA 22529 lorcaserin hydrochloride tablets 10 mg [Internet]. Washington, DC: FDA Endocrinologic and Metabolic Drugs Advisory Committee; 2012 [cited 2015 Jun 23]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303198.pdf.
7. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults - the BLOSSOM trial. J Clin Endocrinol Metab. October 2011;96(10):3067-77. http://dx.doi.org/10.1210/jc.2011-1256
8. Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013;346:f1936. http://doi: 10.1136/bmj.f1936
9. Food and Drug Administration. FDA briefing document NDA 21887 Orlistat Nonprescription Briefing Document [Internet]. Washington: FDA Joint Nonprescription Drugs Advisory Committee and Endocrine and Metabolic Drugs Advisory Committee; 2006 [cited 2015 July 3]. Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4201B1-02-03-FDA-Clinical-Review.pdf.
10. Qnexa NDA. [cited 2015 July 3]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM292317.pdf.
11. Food and Drug Administration. FDA briefing document NDA 22580 Qsyemia QSYMIA (phentermine and topiramate extended-release) capsules [Internet]. Washington, DC: FDA Endocrinologic and Metabolic Drugs Advisory Committee; 2014 [cited 2015 Jun 23]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM312598.pdf.
12. Food and Drug Administration. FDA briefing document NDA 206231 liraglutide injection 3 mg tablets 10 mg [Internet]. Washington, DC: FDA Endocrinologic and Metabolic Drugs Advisory Committee; 2014 [cited 2015 Jun 23]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM413317.pdf.
13. European Medicines Agency. Liraglutide (Saxenda) EPAR Product Information. London: European public assessment reports; 2015 [cited 2015 Jul 4]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003780/WC500185786.pdf.
14. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante RO, Bjørn Jensen C, Wilding JPH. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015 Jul 2;373(1):11-22. http://dx.doi.org/10.1056/NEJMoa1411892